logo-loader
ValiRx PLC

ValiRx wins European patent protection for potential endometriosis treatment

VAL301 is in pre-clinical development as a non-invasive, effective treatment for endometriosis, which affects roughly 5-10% of women in their reproductive years

patent
The European Patent Office has issued a patent notice of allowance for the compound

ValiRx PLC (LON:VAL) has received patent protection in Europe for its pre-clinical therapeutic compound VAL301, which is being lined up as a treatment for endometriosis.

The European Patent Office has issued a patent notice of allowance for the compound, which will be granted once the AIM-listed company has paid the appropriate fees, following on from protection granted in the US last month.

READ: ValiRX raises funds to meet immediate working capital needs and develop drugs

VAL301, which is derived from the company’s in-clinic VAL201, is in late-stage pre-clinical development as a non-invasive, effective treatment for endometriosis, a hugely debilitating gynaecological condition that affects roughly 5-10% of women in their reproductive years and so represents one of the major causes of female infertility

The compound also has the potential to treat other hormone-induced, non-oncological abnormal growth and cell proliferation conditions, such as benign prostatic hyperplasia.

There is substantial global unmet medical need for both of these conditions.

“This is excellent news and I am delighted that the patent portfolio for our lead compounds continues to strengthen, add value and receive further endorsement,” said chief executive Satu Vainikka.

ValiRx shares were up 7% to 0.18p on Thursday morning. 

Quick facts: ValiRx PLC

Price: 0.135 GBX

Market: AIM
Market Cap: £1.38 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Commercial discussions for ValiRx's lead cancer drug progressing 'rapidly'

George Morris, chief operations officer of ValiRx Plc (LON:VAL), tells Proactive's Andrew Scott commercial discussions to take their lead drug VAL 401 into a Phase III trial are progressing rapidly. He says by nature they're detailed and complex but he hopes they'll be completed shortly...

on 6/9/18

RNS

Placing & Issue of Equity

5 days, 11 hours ago

Price Monitoring Extension

1 week, 4 days ago

Half-year Report

3 weeks, 3 days ago

Company Update

3 weeks, 5 days ago

VAL201 Update

on 10/9/19

2 min read